Summit Therapeutics

US · SMMT #1207 by market cap Listed 2015

17.95 +0.64 +3.70%

Live - 5344 symbols - heartbeat 165s ago · 2026-10-08 08:26

Pre-market 17.80 -0.84%

After-hours 17.97 +0.11%

Overnight 17.71 -1.34%

Market cap: 14.32B
P/E (TTM): -16.17
P/B: 22.72
EPS: -1.44
Div yield: 0.00%
52W pos: 34%

Reader sentiment Are you bullish or bearish on SMMT?

Anonymous reader poll. Unscientific, not investment advice.

About Summit Therapeutics

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Founded: 2003
CEO: Mr. Robert W. Duggan
Employees: 265
Headquarters: Miami, Florida, United States of America
Fiscal year end: 12-31
Website: smmttx.com

Company profile

Exchange: US
Symbol: SMMT
Market-cap rank: #1207
Listing date: 2015-03-05
Market cap: 14.32B
Float cap: 2.73B
Shares out: 797.75M
Float shares: 152.29M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:26:21 · For reference only, not investment advice and not tailored to your situation.